A recombinant partial protein (within amino acids 5-140) from the human protein was used as the immunogen for the BATF2 antibody.
Predicted to enable DNA-binding transcription factor activity, RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. Predicted to be involved in defense response to protozoan, myeloid dendritic cell differentiation, and regulation of transcription by RNA polymerase II. Predicted to be part of chromatin. Predicted to be active in nucleus. This antibody recognizes a transcription factor involved in differentiation of CD8+ thymic dendritic cells. BATF2 has been implicated in breast cancer, malignant glioma and metastatis melanoma progression.
